Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Current Opinion in Genetics & Development|March 3, 2012
New perspectives on the biology of fragile X syndromeTao Wang, Steven M Bray, Stephen T WarrenAnnual Review of Pathology|October 25, 2011
Molecular mechanisms of fragile X syndrome: a twenty-year perspectiveMichael R Santoro, Steven M Bray, Stephen T WarrenProceedings of the National Academy of Sciences of the United States of America|August 28, 2010
Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish populationSteven M Bray, Jennifer G Mulle, Anne F Dodd, et al.Nature Chemical Biology|March 11, 2008
Identification of small molecules rescuing fragile X syndrome phenotypes in DrosophilaShuang Chang, Steven M Bray, Zigang Li, et al.Pharmacogenomics|June 8, 2026
Reduction of next-generation sequencing files for efficient pharmacogenotype extractionHargoon N Kaur, Reynold C Ly, Steven M Bray, et al.The Journal of Biological Chemistry|July 11, 2002
Regulation of angiotensin II-induced G protein signaling by phosducin-like proteinJoseph N McLaughlin, Craig D Thulin, Steven M Bray, et al.Cancers|April 3, 2021
Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast CancerPhilip S Bernard, Whitney Wooderchak-Donahue, Mei Wei, et al.American Journal of Medical Genetics. Part A|August 28, 2010
Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed malesStephen C Collins, Steven M Bray, Joshua A Suhl, et al.Pediatric Pulmonology|October 28, 2025
Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer RiskTyler Shugg, Katherine A Gallaway, Nick Powell, et al.Clinical Pharmacology and Therapeutics|March 7, 2026
Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer DrugsFatimah Alhurayri, Islam R Younis, Shadia I Jalal, et al.Pageof 2